Faron Pharmaceuticals Oy banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
Finland FI
Employees
33
IPO date
Nov 17, 2015

Faron Pharmaceuticals is a drug development company focused on medicines that change how the immune system behaves in cancer and severe inflammation. Its main work is to discover and test new drug candidates, especially bexmarilimab, an immunotherapy aimed at helping the body’s own defenses attack tumors. The company is not a mass-market drug seller; it is a research-stage biotech trying to turn lab findings into approved medicines.

Because Faron does not yet have a broad portfolio of approved products, most of its money comes from outside capital, research collaborations, and potential licensing or commercial deals if its drug candidates succeed. In practice, its main “customers” are not patients buying a finished product today, but hospitals, physicians, and partner companies that would use or help develop its therapies in the future. The company’s value comes from advancing clinical programs through testing, regulatory review, and, if successful, eventual commercialization.

What makes Faron’s business different is that it sits at the risky, early end of the pharmaceutical value chain: it creates proprietary drug candidates rather than manufacturing generic medicines or selling established treatments. That means its business depends on scientific results, clinical trial progress, and partner interest, not on steady product sales. If one of its programs works, the company can earn money from drug sales, licensing, or partnerships tied to that medicine.

Faron Pharmaceuticals Oy Investor Relations

Address
Joukahaisenkatu 6
Turku, Lansi-Suomen
Finland

Business Segments

Drug development

Faron Pharmaceuticals develops prescription medicines, mainly for cancer and severe immune-related conditions, and advances them through lab work, clinical trials, and regulatory testing. The company focuses on its own d...

Customers and revenue model

Management

Dr. Juho Markku Jalkanen M.D., MSc, Ph.D.

Founder, CEO & Director

Biography unavailable

Mr. Yrjö Erik Kristian Wichmann M.Sc (Econ.), M.Sc.

Interim Chief Financial Officer

Biography unavailable

Dr. Maija Hollmen Ph.D.

Chief Scientific Officer

Biography unavailable

Mr. Vesa Karvonen L.L.M.

General Counsel

Biography unavailable

Ms. Jennifer Smith-Parker

Head of Communications

Biography unavailable

Dr. Juhana Heinonen

Chief Commercial Officer

Biography unavailable

Dr. Petri Bono M.D., Ph.D.

Chief Medical Officer

Biography unavailable

1 / 7